Methods of treating Kawasaki disease using IL-1beta antibodies

Patent metadata

Field	Value
Publication number	US-9534047-B2
Application number	US-201514861191-A
Country	US
Kind code	B2
Filing date	Sep 22, 2015
Priority date	May 29, 2007
Publication date	Jan 3, 2017
Grant date	Jan 3, 2017

Abstract

This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

First claim

The invention claimed is:

1. A method of treating Kawasaki Disease in a patient in need thereof, comprising administering to said patient an effective amount of a human IL-1 beta binding antibody comprising an antigen binding site comprising:
a) at least one immunoglobulin heavy chain variable domain (V H ) which comprises in sequence hypervariable regions CDR1, CDR2 and CDR3, said CDR1 comprising the amino acid sequence set forth as SEQ ID NO:3, said CDR2 comprising the amino acid sequence set forth as SEQ ID NO:4, and said CDR3 comprising the amino acid sequence set forth as SEQ ID NO:5; and
b) at least one immunoglobulin light chain variable domain (V L ) which comprises in sequence hypervariable regions CDR1′, CDR2′ and CDR3′, said CDR1 comprising the amino acid sequence set forth as SEQ ID NO:6, said CDR2′ comprising the amino acid sequence set forth as SEQ ID NO:7, said CDR3′ comprising the amino acid sequence set forth as SEQ ID NO:8,

wherein said antibody is parenterally administered at a dose between 0.1-50 mg of said antibody per kg body weight of the patient.

2. The method according to claim 1 , wherein the IL-1 beta binding antibody comprises a V H comprising the amino acid sequence set forth as SEQ ID NO:1 and a V L comprising the amino acid sequence set forth as SEQ ID NO:2.

3. The method according to claim 2 , wherein the IL-1beta binding antibody is applied once every week or less frequently.

4. The method according to claim 2 , wherein the IL-1beta binding antibody is applied subcutaneously.

5. The method according to claim 2 , wherein the IL-1beta binding antibody is applied intravenously.

6. The method according to claim 2 , wherein said antibody is administered at a dose between 0.5-20 mg of said antibody per kg body weight of the patient.

7. The method according to claim 6 , wherein said antibody is administered at a dose between 1-10 mg of said antibody per kg body weight of the patient.

8. The method according to claim 7 , wherein said antibody is administered once every month or less frequently.

9. The method according to claim 7 , wherein said antibody is administered once every week or less frequently.

10. The method according to claim 7 , wherein said antibody is administered once every month.

11. The method according to claim 2 , wherein the IL-1beta binding antibody is ACZ885.

Assignees

• Gram Hermann
• Jung Thomas
• Novartis Ag

Inventors

• Gram Hermann
• Jung Thomas

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title